Acute kidney injury

DGAP-News: SphingoTec to Present at the Solebury Trout's Summer Private Company Showcase

Thursday, August 6, 2020 - 12:29pm

Please click the following link to register: https://troutaccess.com/index.php/c/Summer2020PCS

Key Points: 
  • Please click the following link to register: https://troutaccess.com/index.php/c/Summer2020PCS
    SphingoTec GmbH ( "SphingoTec"; Hennigsdorf near Berlin, Germany) develops and markets innovative in-vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as sepsis, acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies.
  • SphingoTec's proprietary biomarker portfolio includes Bioactive Adrenomedullin(bio-ADM(R)), a unique biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, Proenkephalin (penKid(R)), a unique biomarker for real-time assessment of kidney function, and Dipeptidyl Peptidase 3 (DPP3), a unique biomarker for cardiac depression.
  • IVD tests for SphingoTec's proprietary biomarkers are made available as sphingotest(R) microtiterplate tests as well as point-of-care tests on the Nexus IB10 immunoassay platform by SphingoTec's subsidiary Nexus Dx Inc. (San Diego, CA, USA) alongside a broad menu of established and commonly used tests for acute and critical care.
  • For more information please visit our website: https://sphingotec.com/

Angion Enrolls First Patients in Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia

Tuesday, August 4, 2020 - 5:01am

The Phase 2 trial is a multicenter, prospective, randomized, double-blind, placebo-controlled trial to assess safety and efficacy of ANG-3777 in patients hospitalized with confirmed COVID-19 pneumonia.

Key Points: 
  • The Phase 2 trial is a multicenter, prospective, randomized, double-blind, placebo-controlled trial to assess safety and efficacy of ANG-3777 in patients hospitalized with confirmed COVID-19 pneumonia.
  • The clinical rationale for this Phase 2 clinical trial of ANG-3777 in patients with acute lung injury associated with COVID-19 pneumonia is rooted in the compelling activity ANG-3777 has shown in several preclinical in vivo models of acute lung injury such as radiation-induced lung injury, chlorine (Cl2)-induced acute lung injury, bleomycin-induced pulmonary edema, TGF1-induced mortality and lung fibrosis, lipopolysaccharide (LPS)-induced shock, and lung ischemia-reperfusion injury.
  • The ongoing clinical trials of ANG-3777 include a placebo-controlled Phase 3 registration trial in transplant-associated acute kidney injury, also known as delayed graft function, a Phase 2 proof-of-concept trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass surgery, and a Phase 2 proof-of-concept trial in patients with acute lung injury associated with COVID-19 pneumonia.
  • ANG-3777 is currently in clinical trials investigating its impact on acute organ injury, including two forms of acute kidney injury and in acute lung injury.

DGAP-News: SphingoTec to Present at the LifeSci Partners' Summer Symposium

Friday, July 31, 2020 - 12:10pm

Please click the following link to register: https://lifesci.events/SummerSymposium

Key Points: 
  • Please click the following link to register: https://lifesci.events/SummerSymposium
    SphingoTec GmbH ( "SphingoTec"; Hennigsdorf near Berlin, Germany) develops and markets innovative in-vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as sepsis, acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies.
  • SphingoTec's proprietary biomarker portfolio includes Bioactive Adrenomedullin(bio-ADM(R)), a unique biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, Proenkephalin (penKid(R)), a unique biomarker for real-time assessment of kidney function, and Dipeptidyl Peptidase 3 (DPP3), a unique biomarker for cardiac depression.
  • IVD tests for SphingoTec's proprietary biomarkers are made available as sphingotest(R) microtiterplate tests as well as point-of-care tests on the Nexus IB10 immunoassay platform by SphingoTec's subsidiary Nexus Dx Inc. (San Diego, CA, USA) alongside a broad menu of established and commonly used tests for acute and critical care.
  • For more information please visit our website: https://sphingotec.com/

GE Healthcare to Distribute Osprey Medical’s Technology to Address Angiography Based Acute Kidney Injury (AKI)

Thursday, July 30, 2020 - 2:00pm

Ospreys DyeVert contrast minimization devices, complemented by GE Healthcare's range of iodinated x-ray contrast media, offer healthcare professionals a technology platform to address the rising problem of Acute Kidney Injury (AKI) following interventional coronary angiograms in patients with Chronic Kidney Disease (CKD).

Key Points: 
  • Ospreys DyeVert contrast minimization devices, complemented by GE Healthcare's range of iodinated x-ray contrast media, offer healthcare professionals a technology platform to address the rising problem of Acute Kidney Injury (AKI) following interventional coronary angiograms in patients with Chronic Kidney Disease (CKD).
  • GE Healthcare and Osprey share a similar goal rooted in improving patient outcomes added Kevin ONeill, President and CEO of GE Healthcares Pharmaceutical Diagnostics business.
  • Osprey and GE Healthcares portfolios are aligned with these guidelines so that healthcare professionals can help minimize AKI complications in patients with CKD.
  • As Osprey develops new products GE Healthcare will be granted a right of first refusal to distribute and promote these products in the Region.

COVID-19 Kidney Biopsy Research Shows Mostly Tubular Damage With No Presence of Virus in the Tissue

Friday, July 17, 2020 - 8:11pm

The biopsies showed no presence of the virus within the kidney tissue.

Key Points: 
  • The biopsies showed no presence of the virus within the kidney tissue.
  • View the full release here: https://www.businesswire.com/news/home/20200717005523/en/
    Biopsy image showing acute tubular necrosis in a kidney.
  • The kidney biopsy samples revealed the presence of ATN, some with other pathological findings, but no evidence of the virus in the kidney tissue itself.
  • Since kidney injury has been observed in COVID-19 patients, the question of direct viral infection of the kidney has been debated by the medical research community.

CHF Solutions and RenalSense Enter Distribution Partnership to Offer Ultrafiltration and Real-Time Renal Diagnostics

Wednesday, July 8, 2020 - 2:25pm

This information, which reflects changes in renal function, provides an early sign of acute kidney injury (AKI) risk and facilitates rapid intervention.

Key Points: 
  • This information, which reflects changes in renal function, provides an early sign of acute kidney injury (AKI) risk and facilitates rapid intervention.
  • CHF Solutions, Inc. (CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation.
  • RenalSense is a privately owned medical device company dedicated to real-time renal diagnostics.
  • CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Angion Initiates Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia

Wednesday, July 8, 2020 - 5:01am

The Phase 2 trial is a multicenter, prospective, randomized, double-blind, placebo-controlled trial to assess safety and efficacy of ANG-3777 in patients hospitalized with confirmed COVID-19 pneumonia.

Key Points: 
  • The Phase 2 trial is a multicenter, prospective, randomized, double-blind, placebo-controlled trial to assess safety and efficacy of ANG-3777 in patients hospitalized with confirmed COVID-19 pneumonia.
  • The clinical rationale for this Phase 2 clinical trial of ANG-3777 in patients with acute lung injury associated with COVID-19 pneumonia is rooted in the compelling activity ANG-3777 has shown in several preclinical in vivo models of acute lung injury such as radiation-induced lung injury, chlorine (Cl2)-induced acute lung injury, bleomycin-induced pulmonary edema, TGF1-induced mortality and lung fibrosis, lipopolysaccharide (LPS)-induced shock, and lung ischemia-reperfusion injury.
  • The ongoing clinical trials of ANG-3777 include a placebo-controlled Phase 3 registration trial in transplant-associated acute kidney injury, also known as delayed graft function, a Phase 2 proof-of-concept trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass surgery, and a Phase 2 proof-of-concept trial in patients with acute lung injury associated with COVID-19 pneumonia.
  • ANG-3777 is currently in clinical trials investigating its impact on acute organ injury, including two forms of acute kidney injury and in acute lung injury.

Dascena Receives FDA Breakthrough Device Designation for Machine Learning Algorithm for Earlier Prediction of Acute Kidney Injury

Tuesday, July 7, 2020 - 1:00pm

This is the first Breakthrough Device Designation of a cloud-based machine learning algorithm developed for the early detection of AKI.

Key Points: 
  • This is the first Breakthrough Device Designation of a cloud-based machine learning algorithm developed for the early detection of AKI.
  • Acute kidney injury commonly affects hospitalized individuals, and if not caught early, can result in dangerous outcomes for patients, said Ritankar Das, chief executive officer of Dascena.
  • Our machine learning algorithm is able to analyze patient vital sign data and determine whether a patient is at risk of developing acute kidney injury.
  • Dascena is developing machine learning diagnostic algorithms to enable early disease intervention and improve care outcomes for patients.

Dialysis Centers Face Pressure to Deal with Increased Incidences of Kidney Injury Among COVID-19 Patients

Wednesday, July 1, 2020 - 8:15pm

Although the virus primarily affects the lungs, recent studies have shown a high incidence of acute kidney injury among hospitalized patients.

Key Points: 
  • Although the virus primarily affects the lungs, recent studies have shown a high incidence of acute kidney injury among hospitalized patients.
  • Demand for dialysis machines, plastic disposables and filtrate replacement solutions has skyrocketed as hospitals face this new challenge to the treatment of COVID-19 patients.
  • This has forced more people in need of kidney transplants to begin dialysis treatments or to remain on dialysis for longer.
  • This is putting immense pressure on dialysis centers who are struggling to serve their existing patients as well as to meet the new demand.

AM-Pharma Announces the Appointment of Rita Jain M.D. to its Supervisory Board

Wednesday, July 1, 2020 - 10:00am

AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, today announced the appointment of Rita Jain, M.D., to the Companys Supervisory Board.

Key Points: 
  • AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, today announced the appointment of Rita Jain, M.D., to the Companys Supervisory Board.
  • She also currently serves on the board of NASDAQ-listed ChemoCentryx, supporting the company in developing therapeutics targeting inflammatory disorders, autoimmune diseases and cancer.
  • I am impressed by the data and the clinical trial execution demonstrated in AM-Pharmas multinational Phase II STOP-AKI trial in patients with sepsis-associated acute kidney injury, said Rita Jain, M.D.
  • During her tenure at Akebia, a NASDAQ-listed biopharmaceutical company, Dr. Jain led the clinical development program for vadadustat, including the advancement of multiple global pivotal Phase III studies.